StemRad
Lifesaving Protection against Deadly Radiation
StartupStemRad is a Tel Aviv-Yafo-based startup in the Aerospace, Defense & HLS sector, established in 2011. Lifesaving Protection against Deadly Radiation. The company has raised a total of $7.81M across 4 funding rounds, currently at the Mature stage. StemRad was founded by Daniel Levitt and Oren Milstein, PhD. Key investors include Jeff Vinik, Wanaka Capital Partners. The company has 11-50 employees. Core technologies: Materials & Substances.
With $7.81M in total funding, StemRad is a Mature-stage company operating in Aerospace, Defense & HLS. The company follows a B2B/B2G business model. Product stage: Released. The company holds 1 patent.
- StageMature
- ProductReleased
- ModelB2B, B2G
- Employees11-50
- HQTel Aviv-Yafo
- DistrictCenter District
- Last Round$250K
- Jeff Vinik
- Wanaka Capital Partners
Daniel LevittCo-founder & Board Member (founding CEO)Oren Milstein, PhDCo-founder, CEO & CSO
17 articles covered by sources including timesofisrael.com,
hypepotamus.com,
www.calcalistech.com,
www.83degreesmedia.com,
nocamels.com.
What does StemRad do?
StemRad provides personal radiation-protection solutions. Its technology offers lifesaving protection from penetrating ionizing radiation, making the lives of first responders, military personnel, utility personnel, medical teams, and astronauts safer without compromising mission objectives. The company has developed the 360 Gamma, a wearable shield that provides lifesaving protection from gamma radiation. StemRads 360 Gamma lowers radiation exposure to the most critical radiosensitive organs, including the colon, stomach, and ovaries, significantly reducing the associated risks in accordance with the ALARA safety principle. The StemRad 360 Gamma is worn around the pelvic area, which contains the bodys largest concentration of bone marrow. StemRad is also the developer of AstroRad, personal protective equipment designed to be worn by astronauts beyond low Earth orbit. Co-developed by StemRad and Lockheed Martin, AstroRad protects bone marrow to prevent acute radiation sickness, but is further expanded to also protect the lungs, stomach, colon, breasts, and ovaries organs that are particularly vulnerable to the development of cancer due to chronic exposure to radiation.
How much funding has StemRad raised?
StemRad has raised $7.81M in total funding across 4 rounds. The company is currently at the Mature stage. Key investors include Jeff Vinik, Wanaka Capital Partners.
Who founded StemRad?
StemRad was founded in 2011 by Daniel Levitt (Co-founder & Board Member (founding CEO)), Oren Milstein, PhD (Co-founder, CEO & CSO).
What sector is StemRad in?
StemRad operates in Aerospace, Defense & HLS, Defense & HLS Solutions, Combat Equipment & Systems, with core technologies in Materials & Substances. Target customers: Industrial Manufacturing, Discrete Industries, Aerospace, Defense, Safety & Security, Security, Homeland Security, National Security, Civil, Military, Energy, Utilities & Waste Management, New Fuels, Nuclear, Healthcare & Life Sciences, Healthcare, Providers.
Where is StemRad located?
StemRad is based in Raoul Wallenberg Street 4, Tel Aviv-Yafo, Israel, Center District. The company also has offices abroad.